Talk Bio

Genomenon announced a strategic sponsorship from Amicus Therapeutics on March 10, 2026, to accelerate awareness, diagnosis, and research for Fabry disease. 1 Genomenon curated and classified over 1,300 GLA gene variants using AI and expert review, submitting them to ClinVar, with more than 1,000 assessed as pathogenic or likely pathogenic, over 50% new to ClinVar. 1 The variant evidence is freely available via the Mastermind Genomic Intelligence Platform and ClinVar to support faster genetic test interpretation and reduce diagnosis delays. 1 Fabry disease is a rare X-linked lysosomal storage disorder caused by GLA deficiency, leading to globotriaosylceramide accumulation and organ damage; early diagnosis is critical. 1 This is part of Genomenon's Genetic Disease Sponsorship Program to remove barriers to diagnosis for rare diseases by distributing public variant knowledge. 1 Quotes: Amicus CDO Jeff Castelli emphasized accelerating diagnosis with high-quality genetic insi...